✳flâneur — a map of the web's best reading

When and in Whom to Initiate HCV Therapy | HCV Guidance

hcvguidelines.org · 7,374 words · saved by 1 readers

Successful hepatitis C treatment results in sustained virologic response (SVR), which is tantamount to virologic cure and, as such, is expected to benefit nearly all chronically infected persons. When the US Food and Drug Administration (FDA) approved the first interferon-sparing treatment for HCV infection, many patients who had previously been “warehoused” sought treatment. The infrastructure (ie, experienced practitioners, budgeted healthcare dollars, etc) did not yet exist to treat all patients immediately. Thus, the panel offered guidance for prioritizing treatment first for those with the greatest need. Since that time, there have been opportunities to treat many of the highest-risk patients and accumulate real-world experience regarding the tolerability and safety of interferon-free HCV regimens. More importantly, from a medical standpoint, data continue to accumulate that demonstrate the many benefits, both intrahepatic and extrahepatic, that accompany HCV eradication. Therefor

When and in Whom to Initiate HCV Therapy – HCV Guidance By continuing to browse the site you are agreeing to our use of cookies and similar tracking technologies described in our privacy policy . I Accept X Home / Resource Library / Resource When and in Whom to Initiate HCV Therapy Published on February 22, 2017 Resource Details Download Full Guidance Print Page PDF Version This Page Links to Calculators AST to Platelet Ratio Index (APRI) Child-Turcotte-Pugh Fibrosis-4 (FIB-4) Glomerular Filtration Rate (GFR) Model For End-Stage Liver Disease (MELD) Help Abbreviations Successful hepatiti

Explore this link on the map →

related reading